Souhaitez-vous accéder aux communiqués récents ?

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.

All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review

SAN FRANCISCO, March 10, 2026 (GLOBE NEWSWIRE) -- DianaHR, which offers the first AI-powered HR-as-a-Service platform for SMBs, is proud to announce that its founder and CEO, Upeka Bee, has been...

60 Degrees Pharmaceuticals partners with GoodRx to cut ARAKODA® costs up to 30%, expanding affordable malaria prevention at 70,000+ pharmacies.

60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract.

60 Degrees Pharma partners with Runway Health to give international travelers direct telehealth access to once-weekly ARAKODA for malaria prevention.

60 DEGREES PHARMACEUTICALS, INC. ANNOUNCES APPROVAL OF REVERSE STOCK SPLIT RATIO

Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.

60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials